Emerging research suggest this peptide, a dual stimulator targeting both GLP-1 and another hormone, could offer a significant step forward for body management . Initial human trials have shown considerable decreases in abdominal tissue, potentially surpassing existing body composition therapies . However , further assessment is needed to thoroughly